Australia Lung Cancer Diagnostics Market Expected to Grow Significantly by 2033

Renub Research July 14, 2025

11 min read

Renub Research Highlights Rapid Technological Advancements and Rising Cancer Incidence as Key Growth Drivers

Growing Burden of Lung Cancer Fuels Australia’s Diagnostics Market

According to the latest report from Renub Research, the Australia Lung Cancer Diagnostics Market is poised for substantial growth through 2033. As lung cancer remains one of the most commonly diagnosed cancers and a leading cause of cancer-related deaths in Australia, the need for early detection and advanced diagnostic tools is becoming more critical than ever.

Explore the full market insights, growth drivers, and projections in the detailed report:

👉 Australia Lung Cancer Diagnostics Market – Renub Research

Rising Lung Cancer Incidence Amplifies Demand for Early Diagnostic Solutions

Lung cancer is the fifth most commonly diagnosed cancer in Australia but remains the leading cause of cancer deaths, accounting for nearly 20% of all cancer-related fatalities. According to the Australian Institute of Health and Welfare (AIHW), over 13,000 Australians are diagnosed with lung cancer annually, with smoking, air pollution, occupational exposure, and aging population being major contributing factors.

The high mortality rate is primarily due to late-stage diagnosis, which significantly reduces treatment options and survival chances. This has led to increased demand for early screening programs, non-invasive testing methods, and precision diagnostics that can improve early detection and patient outcomes.

Technological Innovations Driving Market Growth

Technological advancements are playing a pivotal role in transforming the lung cancer diagnostics landscape in Australia. Innovations in liquid biopsy, next-generation sequencing (NGS), artificial intelligence (AI) in imaging, and molecular biomarker analysis are enabling faster, more accurate, and minimally invasive diagnostics.

Key innovations include:

Low-dose CT scans for early lung cancer screening
Circulating tumor DNA (ctDNA) tests for real-time monitoring
AI-enabled imaging systems for improved interpretation of chest scans
Companion diagnostics for personalized treatment approaches

These technologies are not only reducing diagnostic delays but also guiding oncologists in tailoring treatment regimens based on genetic profiles, thereby improving survival rates and reducing unnecessary interventions.

Increasing Government and Private Sector Initiatives

Government-led programs and public-private partnerships are actively supporting the expansion of lung cancer diagnostic services in Australia. The National Lung Cancer Screening Program, set to be rolled out nationally, aims to screen high-risk individuals using low-dose computed tomography (LDCT), which is expected to significantly drive the uptake of diagnostic tests.

Additionally, collaborations between diagnostic companies and research institutions are accelerating innovation and access. Increased funding from health agencies and cancer research foundations is being channeled into the development of novel diagnostic tools and clinical validation of biomarkers, further propelling market growth.

Growing Awareness and Changing Lifestyle Habits

Heightened awareness about the dangers of tobacco use and occupational exposure, combined with government campaigns around early cancer detection, has led to a cultural shift among Australians. People are now more proactive about participating in routine health checks and screenings.

Moreover, the integration of telehealth and digital diagnostics—accelerated by the COVID-19 pandemic—has made diagnostic consultations and test interpretations more accessible in remote and underserved regions of Australia. This trend is expected to continue as the healthcare system increasingly adopts digital health models.

Market Segmentation: By Test Type and End Users

The Australia Lung Cancer Diagnostics Market can be segmented by test type and end user, each showing unique trends and growth trajectories.

By Test Type:

Imaging Tests (X-ray, CT Scan, PET Scan, MRI)
Biopsy and Histopathology
Molecular Diagnostic Tests (PCR, NGS, FISH)
Sputum Cytology
Liquid Biopsy
Blood Tests (CEA, CYFRA 21-1, NSE)

Among these, imaging tests continue to dominate due to their critical role in initial detection. However, molecular and liquid biopsy tests are witnessing the fastest growth owing to their accuracy, non-invasive nature, and increasing use in precision oncology.

By End User:

Hospitals
Cancer Diagnostic Centers
Academic and Research Institutes
Independent Diagnostic Laboratories

Hospitals remain the primary testing centers, but specialized cancer diagnostic centers and labs are rapidly expanding their footprint, particularly in urban hubs like Sydney, Melbourne, and Brisbane.

Competitive Landscape: Strategic Collaborations and Technological Edge

The Australian lung cancer diagnostics market is competitive and evolving, with domestic and global players focusing on technological leadership, strategic acquisitions, and clinical partnerships to gain market share.

Leading Companies Include:

Roche Diagnostics
Thermo Fisher Scientific
Illumina, Inc.
Qiagen
GE Healthcare
Agilent Technologies
Siemens Healthineers
Natera, Inc.

These companies are investing in localized R&D, clinical trials, and collaborations with Australian cancer institutes to align with the national cancer control strategies and ensure compliance with Therapeutic Goods Administration (TGA) standards.

Challenges and Opportunities

While the market shows immense potential, it also faces several challenges:

High costs of advanced diagnostic technologies
Limited accessibility in rural and remote regions
Shortage of skilled diagnostic professionals
Lengthy approval and reimbursement processes

Nonetheless, the market presents numerous opportunities:

Expansion of mobile screening units and tele-diagnostics
Greater integration of AI and machine learning in diagnostics
Development of cost-effective point-of-care tests
Government subsidies and private insurance schemes supporting early cancer detection

Future Outlook: Precision Diagnostics and Early Detection at the Forefront

As Australia’s healthcare system continues to prioritize cancer control and early diagnosis, the lung cancer diagnostics market is expected to experience sustained growth and innovation over the next decade. With early detection being the key to improving survival rates, the focus will increasingly shift toward personalized, less invasive, and data-driven diagnostics.

The combination of favorable government initiatives, technological innovation, and increasing patient awareness places Australia in a strong position to lead in advanced cancer diagnostics and care.

To access complete forecasts, segmentation analysis, and detailed company profiles, refer to the full report:

👉 Australia Lung Cancer Diagnostics Market – Renub Research

New Publish Report:

Australia Lung Cancer Diagnostics Market Expected to Grow Significantly by 2033

About the Company

Renub Research is a Market Research and Consulting Company with more than 15 years of experience, especially in international Business-to-Business Research, Surveys, and Consulting. We provide a wide range of business research solutions that help companies make better business decisions. We partner with clients across all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

Our wide clientele includes key players in Healthcare, Travel & Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemicals, Logistics & Automotive, Consumer Goods & Retail, Building & Construction, and Agriculture. Our core team comprises experienced professionals with graduate, postgraduate, and Ph.D. qualifications in Finance, Marketing, Human Resources, Bio-Technology, Medicine, Information Technology, Environmental Science, and more.